

Stockholm, 26 April 2012

Resolutions from Swedish Orphan Biovitrum's ("Sobi") Annual General Meeting (AGM)

The Sobi AGM convened earlier today in Stockholm and voted in favour of the resolutions proposed at the meeting, including:

Adoption of the profit and loss statements and balance sheet and discharge of liability

The AGM adopted the income statement and the balance sheet and approved the proposal to carry forward the retained profits of SEK 4,583,105,488.

The board members and the chief executive officers were discharged from liability for the financial year 2011.

Election of Board of Directors, remuneration to the Directors and election of Auditor

The ordinary board members Adine Grate Axén, Bo Jesper Hansen, Lennart Johansson, Helena Saxon, Hans GCP Shikan and Hans Wigzell were re-elected and Matthew Gantz was elected as new board member. Bo Jesper Hansen was re-elected chairman of the Board.

Matthew Gantz was born 1965 and has a BA from Princeton University and an MBA from Harvard Business School. He is Regional US Executive Vice President and General Manager US in BTG, British Technology Group. Prior to BTG, he was Founder and CEO of Acureon Pharmaceuticals, President and CEO of Hydrabiosciences Inc, VP Europe for Chiron's Biopharmaceutical Division and General Manager for PathoGenesis Europe. Prior to Chiron/PathoGenesis, Matthew held a variety of US sales and marketing roles at Abbott Laboratories Diagnostics Division. Matthew Gantz does not hold any shares or options in the company. He is independent in relation to the company and its management and in relation to the company's principal shareholders.

The AGM approved the compensation to the Board in accordance with the nomination committee's proposal.

PricewaterhouseCoopers AB was elected auditor of Sobi until the end of the annual general meeting 2013.

Nomination Committee

The AGM approved the proposed instructions and charter for the nomination committee.

Principles for remuneration for the management, long-term incentive program and transfer of own shares

The AGM approved the proposed guidelines for remuneration for the management.

The AGM also approved the Board's proposal regarding the implementation of a long-term incentive program, and hedging arrangements in respect of the program including a directed issue of no more than 1,655,136 series C shares, authorisation for the Board to decide on a repurchase of all issued series C shares and transfers of no more than 1,480,136 own common shares to program participants.

The Board's proposal regarding transfer of no more than 88,551 own common shares on the stock exchange for the purpose of covering certain payments, mainly social security contributions, that may occur in relation to the Share Program 2009, was also approved by the AGM.

For full details on each proposal adopted by the AGM please refer to www.sobi.com.

For more information, contact:

Åsa Stenqvist, VP Communications and Investor Relations

Phone: +46 8 697 20 00

Swedish Orphan Biovitrum (Sobi)

Sobi is a leading integrated biopharmaceutical company dedicated to bringing innovative therapies and services to improve the health of rare disease patients and their families. The product portfolio comprises about 45 marketed products as well as projects in the late clinical phase. Key therapeutic areas are Inflammation and Genetics & Metabolism. In 2011, Sobi had revenues of SEK 1.9 billion and around 500 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. More information is available at www.sobi.com.

The above information has been made public in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was released for public distribution on April 26, 2012 at 19:30 p.m. CET.